Meta-analysis of 20 RCTs with 14,995 Metastatic Castrate-sensitive Prostate Cancer patients

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“A systematic review and network meta-analysis of 20 Randomised Controlled Trials (RCTs) with 14,995 Metastatic Castrate-sensitive Prostate Cancer (mCSPC) patients:

• Darolutamide (DARO) triplet that is DARO, docetaxel and Androgen Deprivation Therapy (ADT) offers substantial Overall Survival (OS) benefits, particularly in high-burden patients.
• Subgroup analyses indicate radical local therapy and ADT is optimal for low-burden cases.
• Enzalutamide (ENZ) triplet (ENZ, DOC and ADT) shows superior Progression-free Survival (PFS) in the overall population.
• Notably, adding Androgen-receptor Pathway Inhibitors (ARPIs) to ADT increases severe adverse events, though adding docetaxel doesn’t raise exposure-adjusted incidence rates.
• These findings emphasize the need for tailored treatment strategies, balancing survival benefits with adverse event risks, and reaffirm the importance of integrating systemic and local therapies in mCSPC management.”

Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis published in British Journal of Cancer.

Authors: Tianqi Wang, Xiaoyu Wang, Guixin Ding, Hongquan Liu, Xiaohong Ma, Jian Ma, Yuanshan Cui and Jitao Wu.

Additional information
Source: Emre Yekedüz/X